<div id="readability-page-1">Mid-point pricing is the trend. AgomAb Therapeutics NV (AGMB), a Belgian biotech backed by Pfizer, priced its IPO at $16.00 – the mid-point of its range – last night. That put AgomAb Therapeutics right in step with SpyGlass Pharma (SPG) and Jennifer Garner’s Once Upon a Farm (OFRM) – both IPOs also priced at the mid-point of their respective ranges last night – after a brutal sell-off in the broad U.S. stock market. AgomAb Therapeutics NV (AGMB) priced 12.5 million American Depositary Shares (ADS) at $16.00 each to raise $200 million on Thursday night, Feb. 5, 2026. AgomAb’s ADS are expected to start trading today – Friday, Feb. 6, 2026 – on the NASDAQ. J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen were the joint book-runners. AgomAb Therapeutics NV (AGMB) is developing a pill to treat people with Crohn’s disease with fibrostenosis and an inhaled treatment for people with idiopathic pulmonary fibrosis (IPF). AgomAb will use the IPO’s proceeds to finance the Phase 2 clinical trials for its leading product candidates – ontunisertib (AGMB-129) – its pill for Crohn’s disease – about $120 million earmarked from the IPO – and AGMB-447 – its inhaled treatment for pulmonary fibrosis – about $80 million from the IPO, according to the prospectus. Pfizer owned a pre-IPO stake of 5.73 percent. Pfizer will hold a 4.1 percent stake after the IPO, the prospectus said. AgomAb Therapeutics, like most biotechs at the time they go public, is not profitable: AgomAb Therapeutics reported a net loss of $65.98 million on no product revenue for the 12 months that ended Sept. 30, 2025, according to financial statements in the prospectus. (For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.) Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board. To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message. Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.</div>

AgomAb Therapeutics NV (AGMB) 的首次公开募股（IPO）定价为 16.00 美元，符合中间趋势，通过发行 1250 万份美国存托股票筹集了 2 亿美元。这些资金将用于支持其克罗恩病药丸和用于肺纤维化的吸入治疗的二期临床试验。尽管得到了辉瑞的支持，AgomAb 仍报告了 6598 万美元的净亏损，过去一年没有产品收入。该股票将于纳斯达克开始交易

The IPO Buzz: AgomAb Therapeutics (AGMB) Prices IPO at $16 & Joins ‘The Mid-Point Club’

- AgomAb Therapeutics NV (AGMB) 在 2026 年 2 月 5 日以每股 16.00 美元定价其 IPO。  
- 公司计划利用 IPO 收益为 Crohn 病和肺纤维化的临床试验融资。  
- 其在截至 2025 年 9 月的 12 个月内净亏损 6598 万美元。

IPO Scoop

美国制药 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

辉瑞

标普生物技术 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

医药突破 ETF - ALPS

Direxion Daily Biotech Top 5 Bull 2X ETF

纽交所高增长板生物技术指数 ETF - First Trust

IPO 动态：AgomAb Therapeutics（AGMB）以 16 美元的发行价进行 IPO，并加入了 “中点俱乐部”